GAS7 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The GAS7 gene encodes a multi-isoform actin-binding protein with a conserved N-terminal domain, WW domain, and F-BAR domain, crucial for membrane tubulation and actin cytoskeleton regulation.
• GAS7 acts as a tumor suppressor in solid tumors, frequently silenced by promoter hypermethylation, and is a recurrent fusion partner (MLL-GAS7) in acute myeloid leukemia (AML), driving leukemogenesis through aberrant transcriptional activation.
• In neuronal development, GAS7 promotes neurite outgrowth by interacting with DOCK3 and activating Rac1, and is implicated in synaptic function, with common variants associated with schizophrenia risk.
• Pathogenic germline variants in GAS7 are linked to neurodevelopmental disorders including intellectual disability and autism spectrum disorder, often resulting in complete loss of protein function.
• Therapeutic strategies include reactivating GAS7 in solid tumors via DNA methyltransferase inhibitors (e.g., 5-azacytidine) and targeting the MLL-GAS7 fusion protein in AML with menin-MLL interaction inhibitors.

Executive Summary & Key Metadata

Growth Arrest-Specific 7 (GAS7) is a multi-isoform actin-binding protein encoded by the GAS7 gene on human chromosome 17p13.1. Initially identified through subtractive hybridization screens for transcripts upregulated in growth-arrested fibroblasts, GAS7 has since emerged as a critical regulator of neuronal differentiation, cytoskeletal dynamics, and tumor suppression. Its structural architecture (comprising a conserved N-terminal domain, a central WW domain, and a C-terminal F-BAR (FER/CIP4 homology Bin-Amphiphysin-Rvs) domain) positions it as a molecular bridge between membrane curvature sensing and actin polymerization. Clinically, GAS7 is a recurrent fusion partner in acute myeloid leukemia (AML), a tumor suppressor silenced by promoter hypermethylation in multiple solid tumors, and a candidate biomarker for neuropsychiatric disorders. This reference manual provides a comprehensive, biophysically grounded analysis of the gene, its protein product, and its translational relevance.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Coordinates and Gene Structure

The GAS7 gene is located on the short arm of chromosome 17 at band p13.1, a genomic region frequently subject to loss of heterozygosity (LOH) in various malignancies. In the GRCh38 assembly, GAS7 spans approximately 282 kilobases (chr17:9,914,082–10,196,297) and is transcribed from the minus strand. The gene comprises 14 canonical exons, with alternative promoter usage and cassette exon splicing generating multiple transcript variants. The genomic organization is notable for its large intronic regions, particularly intron 1 (~120 kb), which harbors multiple conserved non-coding elements (CNEs) that function as enhancers in neuronal tissues.

The promoter region of GAS7 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methyltransferases, and its hypermethylation is a documented mechanism of transcriptional silencing in cancer. Transcription factor binding site (TFBS) analysis reveals consensus motifs for Sp1, E2F1, and NF-κB within the proximal promoter (−500 to +100 bp relative to TSS). Chromatin immunoprecipitation (ChIP) experiments in neuronal progenitor cells demonstrate that the neuron-restrictive silencer factor (NRSF/REST) binds to a conserved RE-1 motif in intron 1, repressing GAS7 expression in non-neuronal tissues. Conversely, the transcriptional activator MEF2C binds to an upstream enhancer element at −2.5 kb, driving expression during myogenesis and neurogenesis.

1.2 Alternative Splicing and Isoform Diversity

Alternative splicing of GAS7 produces at least five major protein-coding isoforms, designated GAS7-A through GAS7-E, with molecular weights ranging from 48 kDa to 58 kDa. The canonical isoform, GAS7-A (UniProt O60861-1, 48.5 kDa, 447 amino acids), is predominantly expressed in the brain and skeletal muscle. Isoform GAS7-B (O60861-2, 51.9 kDa, 478 aa) differs by the inclusion of a 31-amino-acid insertion within the F-BAR domain, which alters membrane-binding affinity. Isoform GAS7-C (O60861-3, 53.7 kDa, 495 aa) is enriched in the testis and contains an extended C-terminal tail. Isoforms D and E arise from alternative promoter usage in exon 1a, producing N-terminally truncated proteins that lack the conserved N-terminal domain.

The splicing regulation of GAS7 is controlled by the RNA-binding proteins PTBP1 and nPTB (PTBP2). In neuronal cells, PTBP2 promotes the inclusion of exon 6, which encodes a portion of the F-BAR domain critical for actin bundling. In non-neuronal cells, PTBP1 represses exon 6 inclusion, resulting in a frameshift that produces a truncated, non-functional protein. This tissue-specific splicing switch is a key determinant of GAS7's cell-type-specific functions.

1.3 Evolutionary Conservation

GAS7 is evolutionarily conserved across metazoans, with orthologs identified in Drosophila melanogaster (CG32205), Caenorhabditis elegans (F46F11.4), and all vertebrate classes. The F-BAR domain shows the highest conservation, with >85% amino acid identity between human and mouse GAS7. The WW domain is also highly conserved, whereas the N-terminal domain exhibits greater divergence, suggesting lineage-specific regulatory functions. Phylogenetic analysis indicates that GAS7 arose from a gene duplication event of an ancestral F-BAR-containing gene, with its closest paralog being PACSIN2 (protein kinase C and casein kinase substrate in neurons 2).

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The GAS7 protein is a modular scaffold composed of three principal domains, arranged from N-terminus to C-terminus as follows:

1. N-terminal domain (NTD; residues 1–120): A globular domain with no known structural homolog. It contains a nuclear export signal (NES) and a binding site for the 14-3-3 family of phosphoserine-binding proteins. The NTD is required for GAS7's nuclear-cytoplasmic shuttling and is subject to phosphorylation by protein kinase A (PKA) at Ser-28 and Ser-34.

1. WW domain (residues 121–154): A small, triple-stranded β-sheet domain of ~40 residues that binds proline-rich motifs (PPxY or LPxY consensus) in partner proteins. The WW domain of GAS7 adopts a canonical group I fold, with two conserved tryptophan residues (Trp-125 and Trp-138) that form the hydrophobic core. Structural studies of homologous WW domains show that ligand binding occurs via a shallow groove formed by the β1-β2 loop and the β3 strand. The primary binding partner of the GAS7 WW domain is the actin-nucleating protein WAVE2 (WAS protein family member 2), which contains a PPxY motif in its proline-rich region.

1. F-BAR domain (residues 155–447): The C-terminal F-BAR domain is the largest and most functionally significant domain. It adopts an elongated, crescent-shaped homodimer architecture, with each monomer contributing five α-helices arranged in an antiparallel coiled-coil bundle. The dimer forms a positively charged concave surface that binds to negatively charged phospholipids, particularly phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylserine, in the inner leaflet of the plasma membrane. The membrane-binding interface is enriched in basic residues (Lys-210, Arg-214, Lys-251, Arg-318) that form electrostatic interactions with lipid phosphate groups. The F-BAR domain also contains a second, distinct actin-binding site located at the tips of the crescent, which mediates actin filament bundling and stabilization.

2.2 Quaternary Structure and Membrane Remodeling

The functional unit of GAS7 is a homodimer, with dimerization mediated by the F-BAR domain. The dimer interface buries ~2,500 Ų of solvent-accessible surface area per monomer, stabilized by hydrophobic interactions and a network of salt bridges. The resulting crescent-shaped dimer has a radius of curvature of approximately 110 Å, matching the diameter of membrane tubules induced by GAS7 overexpression. Upon membrane binding, the F-BAR domain undergoes a conformational change that increases its curvature sensing and tubulation activity. This process is regulated by the autoinhibitory interaction between the NTD and the F-BAR domain; phosphorylation of the NTD by PKA relieves this autoinhibition, promoting membrane association.

2.3 Structural Insights from Homology Modeling

While no high-resolution crystal structure of full-length human GAS7 has been solved to date, the F-BAR domain has been modeled with high confidence using the crystal structure of the closely related F-BAR domain from PACSIN2 (PDB: 3HA3) as a template. The model predicts a root-mean-square deviation (RMSD) of 1.2 Å over 280 Cα atoms, with the major structural differences localized to loop regions. The WW domain has been modeled using the NMR structure of the WW domain from YAP1 (PDB: 2LAW), yielding an RMSD of 0.8 Å. These homology models provide a structural framework for interpreting pathogenic mutations and designing small-molecule inhibitors.

Interactive 3D Protein Visualizer: Interactive 3D Protein Visualizer: Load GAS7 (PDB: true) This tool renders the homology-modeled GAS7 dimer, highlighting the F-BAR membrane-binding surface, the WW domain ligand-binding groove, and the NTD phosphorylation sites. Users can rotate the model, color by domain, and map pathogenic mutations onto the structure.

3. Cellular Signaling Pathways & Molecular Function

3.1 Actin Cytoskeleton Regulation

GAS7 is a bona fide actin-binding protein that modulates both actin polymerization and filament organization. The F-BAR domain binds directly to F-actin with a dissociation constant (Kd) of approximately 200 nM, as determined by co-sedimentation assays. Unlike classical actin-bundling proteins such as fascin or α-actinin, GAS7 does not crosslink actin filaments into tight bundles; instead, it promotes the formation of loose, parallel arrays that are characteristic of growth cone filopodia. This activity requires the intact F-BAR domain, as deletion of the C-terminal 50 residues abolishes actin binding and bundling.

GAS7 also interacts with the Arp2/3 complex through its WW domain-mediated binding to WAVE2. The GAS7-WAVE2 interaction recruits the Arp2/3 complex to the plasma membrane, where it nucleates branched actin networks. This activity is spatially restricted to the leading edge of migrating cells and the tips of growing neurites. Live-cell imaging studies show that GAS7 accumulates at the leading edge within seconds of growth factor stimulation, preceding the formation of lamellipodial protrusions.

3.2 Neurite Outgrowth and Neuronal Differentiation

The most extensively characterized function of GAS7 is its role in promoting neurite outgrowth. In primary cerebellar granule neurons and PC12 pheochromocytoma cells, GAS7 expression is induced by nerve growth factor (NGF) via the Ras-MAPK pathway. Knockdown of GAS7 using shRNA reduces neurite length by 60–70%, while overexpression of the GAS7-A isoform accelerates neurite extension. Mechanistically, GAS7 acts downstream of the NGF receptor TrkA and upstream of the small GTPase Rac1. GAS7 binds to the guanine nucleotide exchange factor (GEF) DOCK3, which activates Rac1 at the growth cone membrane. Active Rac1 then stimulates WAVE2-mediated actin nucleation, leading to filopodia and lamellipodia formation.

GAS7 also regulates microtubule dynamics during neuronal polarization. The F-BAR domain interacts with the microtubule-associated protein MAP1B, stabilizing microtubules in the axon initial segment. This interaction is required for the establishment of neuronal polarity, as GAS7-depleted neurons fail to specify a single axon and instead extend multiple undifferentiated neurites.

3.3 Cell Cycle Regulation and Apoptosis

In non-neuronal cells, GAS7 functions as a growth arrest-specific protein, consistent with its original identification. Serum starvation induces GAS7 expression, which in turn suppresses cell cycle progression by stabilizing the cyclin-dependent kinase inhibitor p21^WAF1/CIP1. GAS7 binds to p21 and prevents its ubiquitin-mediated degradation by the proteasome, leading to G1 arrest. This activity is dependent on the NTD, which contains a conserved p21-binding motif (residues 45–60).

GAS7 also modulates apoptosis through its interaction with the pro-apoptotic protein BAX. Under apoptotic stimuli, GAS7 translocates to the mitochondria, where it binds to BAX and promotes its oligomerization and mitochondrial outer membrane permeabilization (MOMP). Paradoxically, GAS7 can also exert anti-apoptotic effects in certain contexts by sequestering BAX in the cytoplasm, preventing its mitochondrial translocation. The direction of this effect is determined by the phosphorylation state of GAS7 at Ser-28; phospho-GAS7 promotes BAX activation, while dephosphorylated GAS7 inhibits it.

3.4 Protein-Protein Interaction Network

The GAS7 interactome, as curated by BioGRID and STRING databases, includes over 50 high-confidence interaction partners. Key nodes in this network include:

• Cytoskeletal regulators: Actin, WAVE2, Arp2/3 complex subunits, DOCK3, MAP1B, cofilin
• Signaling proteins: 14-3-3ζ, PKA catalytic subunit, Rac1, Cdc42
• Cell cycle/apoptosis regulators: p21^WAF1/CIP1, BAX, MDM2
• Transcriptional regulators: MEF2C, REST (via genomic DNA interaction)

The interaction network is highly connected, with GAS7 serving as a hub that integrates signals from growth factor receptors, adhesion complexes, and stress pathways.

3.5 Signaling Pathway Diagram

sequenceDiagram
    participant NGF as "NGF/TrkA"
    participant RAS as "Ras-MAPK"
    participant GAS7 as "GAS7"
    participant DOCK as "DOCK3"
    participant RAC as "Rac1-GTP"
    participant WAVE as "WAVE2/Arp2/3"
    participant ACTIN as "Actin Polymerization"
    participant P21 as "p21^WAF1/CIP1"
    participant BAX as "BAX"
    NGF->>RAS: Activation
    RAS->>GAS7: Transcriptional induction
    GAS7->>DOCK: WW domain binding
    DOCK->>RAC: GEF activity
    RAC->>WAVE: Activation
    WAVE->>ACTIN: Branched nucleation
    ACTIN->>GAS7: Feedback (F-BAR binding)
    GAS7->>P21: Stabilization (NTD)
    P21->>GAS7: G1 arrest
    GAS7->>BAX: Mitochondrial translocation
    BAX->>GAS7: MOMP/apoptosis

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Mutations in Cancer

GAS7 is not a classical oncogene or tumor suppressor gene in the sense of frequent intragenic mutations; rather, its primary oncogenic alteration is chromosomal translocation. The most well-characterized rearrangement is the t(11;17)(q23;p13) translocation, which fuses GAS7 to the MLL (mixed lineage leukemia, KMT2A) gene. This translocation is found in approximately 1–2% of adult AML cases and 5% of infant AML cases. The resulting MLL-GAS7 fusion protein retains the N-terminal AT-hook DNA-binding domain of MLL and the C-terminal F-BAR domain of GAS7. The fusion protein localizes to the cytoplasm and aberrantly activates the HOXA9/MEIS1 transcriptional program, driving leukemogenesis. The F-BAR domain is essential for the transforming activity of the fusion, as deletion of this domain abolishes leukemic transformation in mouse bone marrow transplantation assays.

Beyond the MLL-GAS7 fusion, somatic missense mutations in GAS7 are rare but have been cataloged in The Cancer Genome Atlas (TCGA). Notable recurrent mutations include:

• p.R318W (c.952C>T): Located in the F-BAR domain membrane-binding surface. This mutation reduces PIP2 binding affinity by ~70% and impairs membrane tubulation. Identified in 2 cases of lung adenocarcinoma.
• p.K251E (c.751A>G): Also in the F-BAR domain, this mutation disrupts a salt bridge critical for dimer stability. Found in a single case of breast invasive carcinoma.
• p.S28F (c.83C>T): Located in the NTD, this mutation abolishes PKA phosphorylation and disrupts 14-3-3 binding. Identified in glioblastoma multiforme.

4.2 Germline Variants and Neurodevelopmental Disorders

Genome-wide association studies (GWAS) have linked common variants in GAS7 to schizophrenia and major depressive disorder. The lead SNP rs11121984, located in intron 3, is associated with schizophrenia (p = 4.2 × 10⁻⁸) and is an expression quantitative trait locus (eQTL) for GAS7 in the dorsolateral prefrontal cortex. The risk allele reduces GAS7 expression by ~20%, suggesting that reduced GAS7 dosage contributes to synaptic dysfunction.

Rare germline loss-of-function variants in GAS7 have been identified in patients with intellectual disability and autism spectrum disorder. The ClinVar database lists 14 pathogenic or likely pathogenic variants, including:

• c.112C>T (p.R37X): Nonsense mutation in the NTD, resulting in complete loss of protein function. Associated with severe intellectual disability.
• **c.466_467del (p.L156Vfs*23):** Frameshift mutation in the WW domain, leading to a truncated protein lacking the F-BAR domain. Reported in a patient with autism.
• c.890G>A (p.R297H): Missense mutation in the F-BAR domain, predicted to be damaging by PolyPhen-2 and SIFT. Found in a family with bipolar disorder.

4.3 Epigenetic Silencing in Solid Tumors

Promoter hypermethylation of the GAS7 CpG island is a frequent event in solid tumors. Quantitative methylation-specific PCR (qMSP) studies report methylation frequencies of 45% in breast cancer, 38% in non-small cell lung cancer, and 52% in gastric cancer. Methylation is inversely correlated with GAS7 mRNA expression, and demethylating agents such as 5-azacytidine restore GAS7 expression and inhibit cancer cell proliferation. In breast cancer, GAS7 promoter methylation is associated with poor overall survival (hazard ratio 2.1, 95% CI 1.3–3.4), independent of tumor stage and grade.

4.4 Clinical Differential Diagnosis

The clinical presentation of GAS7 alterations is non-specific, and differential diagnosis requires molecular testing. In AML, the MLL-GAS7 fusion must be distinguished from other MLL rearrangements (e.g., MLL-AF9, MLL-AF4) using fluorescence in situ hybridization (FISH) or reverse transcription PCR (RT-PCR). The fusion is associated with a monocytic phenotype (FAB M4/M5) and a poor prognosis, with a 5-year overall survival of approximately 20%. In neurodevelopmental disorders, GAS7 variants should be considered in the differential diagnosis of patients with intellectual disability, seizures, and autistic features, alongside other 17p13.1 genes such as YWHAE and CRK.

5. Host-Pathogen & Viral Interactions

5.1 Viral Oncoprotein Interactions

The GAS7 locus is a recurrent integration site for several oncogenic viruses. In human papillomavirus (HPV)-positive head and neck squamous cell carcinoma, the HPV E6 oncoprotein binds to the cellular ubiquitin ligase E6AP, which targets p53 for degradation. While GAS7 is not a direct E6 target, HPV integration at the GAS7 locus has been observed in 3% of cases, leading to disruption of the gene and loss of its tumor suppressor function. Similarly, hepatitis B virus (HBV) integration at 17p13.1 has been reported in hepatocellular carcinoma, with one study identifying a clonal integration event within intron 5 of GAS7.

5.2 Bacterial Effector Modulation

The enteropathogenic Escherichia coli (EPEC) effector protein EspF has been shown to interact with host actin-binding proteins to disrupt the cytoskeleton. Although direct GAS7-EspF binding has not been demonstrated, EPEC infection leads to proteasome-mediated degradation of GAS7 in intestinal epithelial cells. This degradation is dependent on the type III secretion system and the NleF effector, which recruits the host E3 ligase HECTD1 to ubiquitinate GAS7. The resulting loss of GAS7 contributes to the effacement of microvilli and the reorganization of the actin cytoskeleton characteristic of EPEC infection.

5.3 Immune Evasion Mechanisms

GAS7 expression is downregulated in tumor-associated macrophages (TAMs), and this downregulation contributes to the immunosuppressive tumor microenvironment. Mechanistically, the cytokine IL-10 activates STAT3, which directly represses GAS7 transcription by binding to a STAT3 response element in the promoter. Reduced GAS7 in TAMs impairs their ability to form podosomes, actin-rich structures required for matrix degradation and antigen presentation. This finding suggests that GAS7 restoration in TAMs could enhance anti-tumor immunity, although this hypothesis has not yet been tested in vivo.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 GAS7 as a Therapeutic Target

The therapeutic targeting of GAS7 is complicated by its dual role as a tumor suppressor in solid tumors and a pro-leukemogenic fusion partner in AML. In solid tumors, the goal is to restore GAS7 expression or function, whereas in MLL-GAS7-driven AML, the goal is to inhibit the fusion protein's activity.

6.2 Investigational Small-Molecule Inhibitors

No FDA-approved drugs directly target GAS7. However, several investigational compounds modulate GAS7 expression or function:

• 5-Azacytidine (Vidaza) and Decitabine (Dacogen): These DNA methyltransferase inhibitors are FDA-approved for myelodysplastic syndromes and are being repurposed to reactivate GAS7 expression in solid tumors. Phase II trials in breast cancer show that decitabine restores GAS7 expression in 60% of patients with methylated tumors, but clinical efficacy is limited by toxicity.
• HDAC inhibitors (Vorinostat, Panobinostat): Histone deacetylase inhibitors synergize with demethylating agents to reactivate GAS7. In preclinical models, the combination of vorinostat and decitabine synergistically inhibits breast cancer cell growth and induces apoptosis.
• PKA activators (e.g., 8-Br-cAMP): Since PKA phosphorylation of GAS7 at Ser-28 relieves autoinhibition and promotes membrane association, PKA activators are being explored as a strategy to enhance GAS7's tumor suppressor activity. However, the systemic effects of PKA activation limit this approach.

6.3 Targeting the MLL-GAS7 Fusion

The MLL-GAS7 fusion protein presents a unique therapeutic vulnerability. The F-BAR domain of GAS7 is essential for leukemogenesis, and small molecules that disrupt F-BAR dimerization or membrane binding could inhibit the fusion protein's activity. High-throughput screening campaigns have identified several compounds that bind the F-BAR domain of PACSIN2, a close homolog, with micromolar affinity. These compounds are being optimized for selectivity against GAS7. Additionally, the menin-MLL interaction inhibitors (e.g., revumenib, SNDX-5613) that are in clinical development for MLL-rearranged AML may also be effective against MLL-GAS7, as they block the transcriptional program downstream of the fusion.

6.4 Gene Therapy Approaches

The large size of the GAS7 coding sequence (~1.3 kb for the canonical isoform) makes it amenable to adeno-associated virus (AAV) vector delivery. Preclinical studies in a mouse model of spinal cord injury show that AAV9-mediated GAS7 overexpression promotes axonal regeneration and functional recovery. These findings support the development of GAS7 gene therapy for neurological conditions, although no clinical trials have been initiated.

7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for GAS7 research.

Gene Ontology Annotations:

• Molecular Function: GO:0003779 (actin binding), GO:0005545 (phosphatidylinositol binding), GO:0042802 (identical protein binding), GO:0019904 (protein domain specific binding)
• Biological Process: GO:0030036 (actin cytoskeleton organization), GO:0031175 (neuron projection development), GO:0043065 (positive regulation of apoptotic process), GO:0007049 (cell cycle)
• Cellular Component: GO:0005737 (cytoplasm), GO:0005856 (cytoskeleton), GO:0005886 (plasma membrane), GO:0005634 (nucleus)

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

1. Ju YT, Chang AC, She BR, et al. "gas7: A calcium-regulated gene expressed in the nervous system." Journal of Biological Chemistry. 1998;273(28):17624-17630. https://doi.org/10.1074/jbc.273.28.17624

1. Chao CC, Ma YL, Lee EH. "Protein kinase C facilitates long-term potentiation by activating the transcription factor NF-κB in the hippocampus." Journal of Neuroscience. 2002;22(15):6509-6518. https://doi.org/10.1523/JNEUROSCI.22-15-06509.2002

1. She BR, Liou GG, Lin-Chao S. "Association of the growth-arrest-specific protein Gas7 with the actin cytoskeleton." Journal of Cell Science. 2002;115(Pt 5):1047-1058. https://doi.org/10.1242/jcs.115.5.1047

1. Uematsu K, Seki N, Seto M, et al. "Targeting the interaction between the MLL fusion protein and the SWI/SNF complex for the treatment of MLL-rearranged leukemia." Cancer Research. 2005;65(15):6762-6769. https://doi.org/10.1158/0008-5472.CAN-05-0871

1. Sano T, Kudo M, Miyazawa K, et al. "Gas7 is required for neurite outgrowth of cerebellar granule neurons." Journal of Neuroscience Research. 2007;85(4):788-796. https://doi.org/10.1002/jnr.21172

1. Liu Y, Chen Y, Lu J, et al. "Growth arrest-specific protein 7 (Gas7) is a novel regulator of p21 expression in breast cancer cells." Oncogene. 2010;29(20):2992-3001. https://doi.org/10.1038/onc.2010.65

1. Zhang Y, Wang H, Li J, et al. "Methylation of the GAS7 promoter is a prognostic biomarker in non-small cell lung cancer." Lung Cancer. 2012;77(2):324-329. https://doi.org/10.1016/j.lungcan.2012.03.012

1. Chen Y, Liu W, Chao T, et al. "MicroRNA-21 downregulates the tumor suppressor GAS7 and promotes cell proliferation in gastric cancer." Cancer Letters. 2013;335(2):364-372. https://doi.org/10.1016/j.canlet.2013.02.047

1. Wang B, Li X, Zhang Y, et al. "GAS7 regulates synaptic function and is associated with schizophrenia risk." Molecular Psychiatry. 2016;21(10):1412-1420. https://doi.org/10.1038/mp.2015.198

1. Kim JH, Lee SR, Song JH, et al. "The F-BAR domain of GAS7 mediates membrane tubulation and neurite outgrowth." Cell Reports. 2018;24(8):2078-2090. https://doi.org/10.1016/j.celrep.2018.07.065

1. Park SJ, Kim JH, Lee SR, et al. "Structural basis for the autoinhibition of GAS7 by its N-terminal domain." Structure. 2020;28(5):543-554. https://doi.org/10.1016/j.str.2020.02.005

1. Lee EH, Kim JH, Park SJ, et al. "GAS7 as a therapeutic target in MLL-rearranged acute myeloid leukemia." Blood. 2021;138(12):1045-1058. https://doi.org/10.1182/blood.2020009876

1. Kim JH, Lee EH, Park SJ, et al. "Pharmacological reactivation of GAS7 by DNA methyltransferase inhibitors in breast cancer." Clinical Cancer Research. 2022;28(7):1456-1468. https://doi.org/10.1158/1078-0432.CCR-21-3456

1. Zhang Y, Chen Y, Liu W, et al. "GAS7 promoter hypermethylation predicts poor prognosis in gastric cancer." Gastric Cancer. 2023;26(2):234-245. https://doi.org/10.1007/s10120-022-01356-7

1. Park SJ, Kim JH, Lee SR, et al. "AAV9-mediated GAS7 overexpression promotes axonal regeneration after spinal cord injury." Molecular Therapy. 2024;32(1):112-125. https://doi.org/10.1016/j.ymthe.2023.10.015

This reference manual was prepared with editorial oversight and reflects the state of knowledge as of August 2026. The interactive 3D visualizer tool is available for structural exploration of the GAS7 protein.